 |  |  |  |  |  |  |  |
| The Pan-Asian Network for Neglected Disease PAN4ND |
Recent Meeting Natural Substances meeting in Malaysia |
P
A
N
4
N
D
A
N
4
N
D
PAN4ND's Mission
The PAN4ND network serves to encourage research collaboration between member
institutions to maximize the potential for discovery of hits and leads from Natural
Products for development as drugs for Neglected Diseases.
The PAN4ND network serves to encourage research collaboration between member
institutions to maximize the potential for discovery of hits and leads from Natural
Products for development as drugs for Neglected Diseases.
Coordinator of network: DNDi
The network is coordinated by The Drugs for Neglected Diseases Initiative (DNDi), a
not-for-profit drug development partnership based in Geneva.
Founded in 2003 to address the needs of patients with the most neglected diseases,
DNDi is a collaborative drug R&D organization that is currently developing new
treatments against sleeping sickness (human African trypanosomiasis, HAT), visceral
leishmaniasis (VL), Chagas disease, and malaria.
The primary objective of DNDi is to deliver six-to-eight new treatments by 2014 for
these diseases and to establish a strong R&D portfolio that addresses patient needs.
In doing this, DNDi has two other objectives:
portfolio-based approach that facilitates basic science, preclinical, and clinical
research on targeted diseases.
With industrial partners, DNDi is delivering two new fixed-dose antimalarial
combinations this year: to learn more, visit www.dndi.org or www.actwithasaq.org.
The network is coordinated by The Drugs for Neglected Diseases Initiative (DNDi), a
not-for-profit drug development partnership based in Geneva.
Founded in 2003 to address the needs of patients with the most neglected diseases,
DNDi is a collaborative drug R&D organization that is currently developing new
treatments against sleeping sickness (human African trypanosomiasis, HAT), visceral
leishmaniasis (VL), Chagas disease, and malaria.
The primary objective of DNDi is to deliver six-to-eight new treatments by 2014 for
these diseases and to establish a strong R&D portfolio that addresses patient needs.
In doing this, DNDi has two other objectives:
- To use and strengthen existing capacities in disease-endemic countries via
project implementation - To raise awareness about the need to develop new drugs for neglected
diseases and particularly to advocate for increased public responsibility
portfolio-based approach that facilitates basic science, preclinical, and clinical
research on targeted diseases.
With industrial partners, DNDi is delivering two new fixed-dose antimalarial
combinations this year: to learn more, visit www.dndi.org or www.actwithasaq.org.
|
PAN4ND's Primary Objectives
- To link Natural Products
researchers and institutes as
a collaborative network
- To incorporate Neglected
Diseases into our drug
candidate screening programs
- To standardize network
screening methodologies
against Parasitic Targets and
other pathogens
| How PAN4ND works |
Who Funds Us?
The Sasakawa Peace Foundation has provided and continues to provide the
funding necessary for the creation and upkeep of PAN4ND.
The Sasakawa Peace Foundation has provided and continues to provide the
funding necessary for the creation and upkeep of PAN4ND.